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A propensity score (PS) model’s ability to control confounding can be assessed by evaluating covariate balance
across exposure groups after PS adjustment. The optimal strategy for evaluating a disease risk score (DRS) mod-
el’s ability to control confounding is less clear. DRS models cannot be evaluated through balance checks within
the full population, and they are usually assessed through prediction diagnostics and goodness-of-fit tests. A pro-
posed alternative is the “dry-run” analysis, which divides the unexposed population into “pseudo-exposed” and
“pseudo-unexposed” groups so that differences on observed covariates resemble differences between the actual
exposed and unexposed populations. With no exposure effect separating the pseudo-exposed and pseudo-
unexposed groups, a DRS model is evaluated by its ability to retrieve an unconfounded null estimate after adjust-
ment in this pseudo-population. We used simulations and an empirical example to compare traditional DRS
performance metrics with the dry-run validation. In simulations, the dry run often improved assessment of con-
founding control, compared with the C statistic and goodness-of-fit tests. In the empirical example, PS and DRS
matching gave similar results and showed good performance in terms of covariate balance (PS matching) and
controlling confounding in the dry-run analysis (DRS matching). The dry-run analysis may prove useful in evaluat-
ing confounding control through DRS models.
causal inference; disease risk score; epidemiologic methods; prognostic score; propensity score
Abbreviations: DRS, disease risk score; PS, propensity score.
Summary scores that reduce baseline covariate informa-
tion to a single dimension have become increasingly popular
to control confounding in nonexperimental studies. The pro-
pensity score (PS), defined as the conditional probability
of exposure given a set of observed covariates, has been the
most widely used summary score (1, 2). An alternative to
the PS is the prognostic score, often referred to as the dis-
ease risk score (DRS). Unlike the PS, which summarizes
covariate associations with exposure, the DRS summarizes
covariate associations with potential outcomes (3). Both the
PS and the DRS control for confounding by acting as balanc-
ing scores. Rosenbaum and Rubin (1) showed that, upon
conditioning on the PS, covariates are independent of, or bal-
anced across, exposure groups. Hansen (3) showed that the
DRS acts as a “prognostic balancing” score in that, condi-
tional on the DRS, covariates are independent of the poten-
tial outcome under the control condition. Here, we will refer
to the control condition as unexposed.
The DRS has not been as widely used as the PS for con-
founding control, but it can be advantageous in certain set-
tings. The DRS provides a natural measure to evaluate effect
measure modification (4–6). Although the PS allows re-
searchers to detect and account for effect modification, it
does not provide the best information for health-care provid-
ers in determining what subgroups of the patient population
are most likely to benefit from a given exposure or treatment.
Further, conditioning on the PS can be more restrictive than
conditioning on the DRS (3, 7). A DRS-matched or stratified
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analysis can potentially allow researchers to compare a larger
proportion of the population across exposure groups com-
pared with PS analyses (7).
In practice, the PS and DRS are unknown and must be es-
timated from the available data. While both the estimated
PS and DRS are susceptible to model misspecification, the
DRS is particularly vulnerable because of the need to ex-
trapolate and make additional assumptions when fitting the
risk model (discussed further below) (3). Assessing the va-
lidity of fitted DRS models could improve the robustness of
DRS analyses; however, although a number of studies have
discussed and analyzed methods for evaluating PS models
(8–14), there remains little discussion of how DRS models
should be evaluated when the goal of the DRS is to control
for confounding bias.
In this study we used simulations to compare metrics for
evaluating DRS models in their ability to control confound-
ing. We compared traditional metrics for evaluating risk
models with an alternative strategy termed the “dry-run” analy-
sis (15). We demonstrate the discussed concepts through an
empirical example comparing dabigatran with warfarin for
preventing ischemic stroke and all-cause mortality within a
population of Medicare beneficiaries.
METHODS
Modeling the DRS
The DRS has typically been estimated either by fitting a
regression model within the unexposed population and then
extrapolating this model to predict disease risk for the full
cohort or by fitting a regression model within the full cohort
as a function of baseline covariates and exposure and then
assigning risk scores after setting exposure status to zero
(16–22). Hansen (3) discussed limitations to these strategies,
both of which are examples of “same-sample” estimation. If
the exposure effect is misspecified when fitting the risk
model to the full cohort (e.g., omitting exposure-covariate
interactions), then the estimated scores can carry informa-
tion about the exposure effect. This nonancillarity in the es-
timated risk scores can potentially bias effect estimates and
generate spurious suggestions of effect modification across
levels of disease risk (3, 20). Fitting the DRS only to the un-
exposed population, however, can lead to overfitting, which
can itself cause apparent effect modification and bias overall
in effect estimates (3, 23, 24).
To avoid these problems, both Hansen (3) and Glynn
et al. (23) have proposed using a historical set of unexposed
subjects to fit the DRS model. This strategy can circumvent
the problems associated with “same-sample” estimation, but
it assumes that the effects of risk factors on the outcome,
disease surveillance, and covariate definitions do not change
over time. Violation of these assumptions could result in an
estimated DRS model that is not generalizable to the study
cohort (7, 25, 26).
These challenges in estimating the DRS highlight the im-
portance of evaluating the validity of fitted DRS models as a
way to control confounding. While a PS model’s ability to
control confounding can be evaluated directly by assessing
covariate balance across exposure groups after PS adjustment,
the prognostic balance resulting from a DRS model can be
evaluated only among unexposed individuals, where the po-
tential outcome under the unexposed condition is observed.
Evaluating prognostic balance among only the unexposed can
reward models that are overfitted to the unexposed group and
does not necessarily indicate how well prognostic balance is
achieved within the entire study population (3, 24). Conse-
quently, fitted DRS models have been assessed primarily by
using prediction diagnostics and goodness-of-fit tests rather
than measures of prognostic balance.
The “dry-run” analysis
Hansen (15) proposed an alternative strategy for evaluating
risk scores in their ability to control confounding. Because
modeling the PS does not share the same theoretical challenges
as modeling the DRS, Hansen (15) explained that researchers
can use the estimated PS to divide the unexposed population
into “pseudo-exposed” and “pseudo-unexposed” groups in or-
der to create differences on observed covariates that are similar
to differences between the actual exposed and unexposed
populations. With no exposure effect separating the pseudo-
exposed and pseudo-unexposed groups, analysts can perform
a dry-run analysis by fitting the DRS model to the pseudo-
unexposed group, or a historical set of unexposed subjects,
and then evaluating the validity of the risk score setup by its
ability to control confounding within the pseudo-population. If
subclassification or matching on the estimated DRS results in
unconfounded null effect estimates within the pseudo-
population, then the modeling procedure should be successful
in controlling confounding on the same observed covariates
when applied to the original sample. We describe the dry-run
analysis in detail below and provide example code in Web
Appendix 1 (available at http://aje.oxfordjournals.org/):
1. Estimate the PS within the full study population. This
step entails diagnosing the PS model’s validity (e.g.,
checking positivity violations, calibration, discrimin-
ation, covariate balance, etc.).
2. Create a pseudo-exposure group by sampling, without re-
placement, a subset of unexposed subjects with sampling
probabilities arranged so that the odds of selection for
pseudo-exposure are proportional to the odds of the esti-
mated PSs from step 1. Sampling should be done so that
the proportion of the pseudo-exposed within the full un-
exposed population is approximately equal to the propor-
tion of the exposed within the full study population.
Here, we describe a simple procedure that uses indepen-
dent Bernoulli sampling to select the pseudo-exposure
group. Other sampling procedures could also be em-
ployed (see Web Appendix 1).
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where nu and ne represent the number of unexposed and
exposed individuals in the full population). Conduct a
single independent Bernoulli trial for each unexposed
subject, i, with probability πi, to determine whether sub-
ject i is selected into the pseudo-exposure group. This
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sampling results in an expected size of ⎡⎣ ⎤⎦+ n
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n n u
e
u e
sub-
jects for the pseudo-exposure group but will vary around
this target from sample to sample.
3. Form a pseudo-unexposed group consisting of all indivi-
duals in the unexposed population who are not sampled
into the pseudo-exposure group.
4. Model the DRS within the pseudo-unexposed group or
an external set of unexposed subjects.
5. Estimate the pseudo-exposure effect after stratifying or
matching on the estimated DRSs within the pseudo-
population, and calculate the pseudo-bias, defined as the
difference between the pseudo-effect estimate and the
true null effect.
6. Bootstrap (i.e., repeat) steps 2–5 to form a distribution of
calculated pseudo-biases whose mean and corresponding
confidence limits can be used to evaluate the validity of
the fitted DRS model.
The sampling outlined above results in a pseudo-population
in which the odds of selection for pseudo-exposure are pro-
portional to the estimated odds of exposure in the full popu-
lation. The goal of the dry-run sampling is not to create
pseudo-exposed and pseudo-unexposed groups where co-
variate distributions mirror those of the full exposed and un-
exposed populations, but rather it is to create differences
between the pseudo-exposed and pseudo-unexposed groups
that are similar to observed differences in the full population.
For example, suppose we have a cohort where the average
age among the exposed is 50 years, the average age among
the unexposed is 40 years, and there are equal numbers of
exposed and unexposed. The goal of the dry-run sampling is
to create pseudo-exposed and pseudo-unexposed groups that
differ by 10 years on average, matching the difference be-
tween the exposed and unexposed. That could happen with
a mean age of 45 years within the pseudo-exposed and 35
years within the pseudo-unexposed, resulting in a difference
of 10 years while maintaining the overall average of 40
years across unexposed subjects.
Therefore, prior to mounting a full dry-run validation,
analysts should check that differences in baseline character-
istics between the pseudo-exposed and pseudo-unexposed
groups resemble differences between the actual exposed and
unexposed populations. If the PS model is well-specified,
while positivity assumptions hold also, there should be such
a similarity. It will of course be inexact; one is looking for
gross departures here.
Simulation study
We simulated a dichotomous exposure (A) and outcome
(Y), 6 binary covariates ( )X X X X X X, , , , ,1 3 5 6 8 10 and 4
standard-normal covariates ( )X X X X, , ,2 4 7 9 . We defined
the conditional probability of exposure and outcome accord-
ing to equations 1 and 2.
( [ | ]) = α + α + ⋯ + α + α
+ α + α + α + α ( )
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The coefficient values for αi and βi, i = 1 . . . 15, were se-
lected by drawing values from separate uniform(−0.7, 0.7)
distributions. This range of values (i.e., potentially ranging
from −0.7 to 0.7) was chosen to reflect the range for the ma-
jority of coefficient values observed in an empirical example
comparing dabigatran with warfarin that is described in the
next section. We repeated this process 100 times by drawing
a separate set of values for αi and βi, i = 1 . . . 15, to consider
a total of 100 unique parameter combinations. To avoid is-
sues with the collapsibility of the odds ratio, we held the ex-
posure effect constant at an odds ratio of 1 (i.e., β = 0A )
(27). Both α0 and β0 were set so that the baseline prevalence
of exposure and baseline incidence of the outcome were
30% (i.e., baseline prevalence and incidence when all co-
variate values are set to 0).
With each parameter combination we simulated a study
cohort and a historical set of unexposed subjects that was
similar to the study cohort but with no exposure in-
troduced. We fitted 32 unique DRS models within this his-
torical population using logistic regression with various
degrees of model misspecification. Each of the models
included main effects for the covariates X1 through X10 but
different sets of higher-order terms. We considered all
possible combinations of the higher-order terms shown in
equation 2 (32 in total). We evaluated the calibration and
discrimination for each DRS model by calculating the
Hosmer-Lemeshow P value and C statistic within the ori-
ginal cohort. We also evaluated each DRS model by con-
ducting a dry-run validation as described previously.
Because the dry-run analysis relies on using the PS to cre-
ate the sampling probabilities, we estimated the PS using 4
different logistic models with varying degrees of misspecifica-
tion: PS model 1 (included all higher-order terms), PS model 2
(excluded 1 interaction term), PSmodel 3 (excluded 1 interaction
term and 1 quadratic term), and PS model 4 (excluded all higher-
order terms).
We conducted simulations using sample sizes of 10,000,
5,000, and 2,000. We estimated the exposure effect within the
original study population and each of the pseudo-populations
after stratifying on quintiles of the estimated DRS and after
matching on the estimated DRS. One-to-one caliper match-
ing was done without replacement using a caliper width of
0.2 standard deviations of the respective DRS distribution
(28, 29).
For each of the 100 parameter scenarios, we simulated 100
data sets and evaluated the correlation between the mean of
each of the described measures and the mean bias in the effect
estimates across all simulation runs. Because the C statistic
and Hosmer-Lemeshow P value do not take the direction of
confounding into account, we also evaluated the correlation
between the mean of each measure and the mean absolute
bias in the effect estimates across all simulation runs (the ab-
solute pseudo-bias was used when comparing with the abso-
lute bias).
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Empirical example
We compared the performance of dabigatran versus war-
farin in a nonselected population of older US adults using a
20% random sample (n = 67,667) of all patients with fee-
for-service Medicare parts A (hospital), B (outpatient), and
D (pharmacy) coverage for at least 1 month from October
19, 2010, through December 31, 2012. Details of the study
population and cohort creation are provided elsewhere (7).
We modeled the 1-year risk of combined ischemic stroke
and all-cause mortality within a historical population of new
warfarin users (30) with an index date prior to the introduction
of dabigatran (from January 1, 2008, through October 18,
2010). This model was then used to predict the disease risk for
all individuals within the study cohort. We fitted PS and DRS
models that included main effects for 37 a priori selected cov-
ariates and an additional 200 empirically selected covariates
that were identified within Medicare files containing medica-
tion claims, inpatient and outpatient diagnostic codes, and pro-
cedural codes. The estimated scores were implemented using
1-to-1 matching without replacement. Details of covariate se-
lection and definitions are provided elsewhere (7).
To evaluate the validity of the fitted DRS model, we cre-
ated a pseudo-exposure group by sampling new warfarin
users within the original study cohort (i.e., index date after
October 18, 2010), using the sampling described previously.
We created a pseudo-unexposed group consisting of new
warfarin users who were not selected into the pseudo-
exposure group. We then evaluated the validity of the histor-
ically fitted DRS model by observing how well matching on
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Figure 1. Box plots of the Spearman rank correlation coefficients when stratifying on the estimated disease risk score. Each box plot contains
100 correlation coefficients (1 for each of the 100 parameter combinations considered in the simulation), showing results when considering sam-
ple sizes of 10,000 ((A) and (B)); 5,000 ((C) and (D)); and 2,000 ((E) and (F)). The box plots show correlation coefficients when comparing each
metric with the absolute bias ((A), (C), and (E)) and bias ((B), (D), and (F)) in the effect estimate. Pseudo1 and abs.Pseudo1 represent the
pseudo-bias and absolute pseudo-bias when PS model 1 (including all higher-order terms) was used to create the pseudo-population; Pseudo2
and abs.Pseudo2 correspond to PS model 2 (excluding 1 interaction term); Pseudo3 and abs.Pseudo3 correspond to PS model 3 (excluding 1
interaction and 1 quadratic term); and Pseudo4 and abs.Pseudo4 correspond to PS model 4 (excluding all higher-order terms).
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the estimated scores controlled for confounding within the
pseudo-population. We bootstrapped this process 1,000
times and took the mean of the pseudo-bias across all boot-
strapped runs as the measure for model fit. For comparison,
we also evaluated the performance of the estimated DRSs
by assessing the calibration (Hosmer-Lemeshow goodness-
of-fit test) and discrimination (C statistic) of the predicted
values within the original study cohort.
RESULTS
Simulation results
Figures 1 and 2 show box plots for the Spearman correla-
tion coefficients between each of the described measures
and both the absolute bias (Figure 1A, 1C, and 1E) and bias
(Figure 1B, 1D, and 1F) in the estimated exposure effect.
The absolute pseudo-bias was used when comparing mea-
sures with the absolute bias. In Figure 1, exposure effects
were estimated through DRS stratification, while in Figure 2
the exposure effects were estimated through DRS matching.
Each box plot shows the distribution of 100 correlation coef-
ficients (1 correlation coefficient for each of the 100 para-
meter combinations).
When the estimated PS was a close approximation to the
true PS model (PS models 1 and 2), there was a strong cor-
relation between the pseudo-bias and the actual bias within
the original study cohort (Figures 1 and 2). As the misspeci-
fication in the PS model increased, the strength of this cor-
relation became less pronounced and the C statistic showed
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Figure 2. Box plots of the Spearman rank correlation coefficients when matching on the estimated disease risk score. Each box plot contains
100 correlation coefficients (1 for each of the 100 parameter combinations considered in the simulation), showing results when considering sam-
ple sizes of 10,000 ((A) and (B)); 5,000 ((C) and (D)); and 2,000 ((E) and (F)). The box plots show correlation coefficients when comparing each
metric with the absolute bias ((A), (C), and (E)) and bias ((B), (D), and (F)) in the effect estimate. Pseudo1 and abs.Pseudo1 represent the
pseudo-bias and absolute pseudo-bias when PS model 1 (including all higher-order terms) was used to create the pseudo-population; Pseudo2
and abs.Pseudo2 correspond to PS model 2 (excluding 1 interaction term); Pseudo3 and abs.Pseudo3 correspond to PS model 3 (excluding 1
interaction and 1 quadratic term); and Pseudo4 and abs.Pseudo4 correspond to PS model 4 (excluding all higher-order terms).
Am J Epidemiol. 2017;185(9):842–852
846 Wyss et al.
a stronger correlation in predicting bias (Figures 1 and 2).
Compared with DRS stratification, matching on the esti-
mated DRSs resulted in a weaker correlation between the
pseudo-bias and actual bias in the effect estimate (Figures 1
and 2). The pseudo-bias showed a stronger correlation with
bias in the effect estimate compared with the correlation be-
tween the absolute pseudo-bias and absolute bias in the effect
estimate (Figures 1 and 2). As the sample size decreased, the
correlation between the pseudo-bias and bias in the effect es-
timate was attenuated, but the pseudo-bias was still generally
stronger in predicting bias compared with the C statistic and
Hosmer-Lemeshow P value.
Figure 3 shows each measure plotted against the absolute
bias (Figure 3A, 3C, and 3E) and bias (Figure 3B, 3D, and 3F)
in the effect estimate after combining the values for each meas-
ure across all parameter combinations and models. For ex-
ample, for Figure 3A and 3B we calculated 3,200 pseudo-bias
measures (32 DRS models × 100 parameter combinations)
when using PS model 1 to create the pseudo-populations.
Figure 3A and 3B plot the absolute pseudo-bias (Figure 3A)
and pseudo-bias (Figure 3B) under PS model 1 against the
corresponding absolute bias (Figure 3A) and bias (Figure 3B)
in the exposure effect estimate from the original study cohorts.
Similar descriptions can be applied to Figure 3C and 3D for
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Figure 3. Metrics for evaluating DRSmodels plotted against the absolute bias((A), (C), and (E)) and bias ((B), (D), and (F)) in the effect estimate.
Each point represents a value for the given metric (e.g., C statistic) and the corresponding bias in the treatment effect estimate. Each subplot con-
tains values across all parameter combinations for each of the 32 fitted DRS models. The actual bias in the treatment effect estimate and pseudo-
bias were calculated after matching the estimated disease risk scores. Pseudo-bias 1 in (A) corresponds to PS model 1 (including all higher-order
terms). The line in each plot is the fitted least squares regression.
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the C statistic and Figure 3E and 3F for the Hosmer-Lemeshow
P value. Similar to Figures 1 and 2, when the estimated PS was
correctly specified, the pseudo-bias showed the strongest corre-
lation with bias and had an intercept from the least-squares
regression line of approximately 0 (Figure 3A and 3B). Both
the C statistic and the P value from the Hosmer-Lemeshow test
showed weaker correlations after combining results across dif-
ferent data-generating models (Figure 3C–3F).
Figures 1 and 2 show that the value of the dry-run pseudo-
bias as an indication for bias in the full study cohort is
affected by the specification of the PS model and sample
size. To examine other factors that may influence the per-
formance of the dry-run analysis in more detail, we con-
ducted a number of sensitivity analyses where we varied the
prevalence of exposure, the degree of separation in the PS
distributions, the correlation between the PS and DRS, and
the exposure effect. A detailed description of these additional
simulations is provided in Web Appendix 2. Results showed
that the prevalence of exposure, separation in PS distribu-
tions, and correlation between the PS and DRS can also
influence the performance of the dry-run analysis. When the
PS was correctly specified, however, the pseudo-bias gener-
ally performed well in predicting bias in the effect estimate
compared with the C statistic and Hosmer-Lemeshow P value
(Web Figures 1–8).
Empirical results
We present results for the empirical study in Figure 4 and
Tables 1 and 2. Figure 4 shows good overlap in PS distribu-
tions across the dabigatran (exposed) and warfarin (unexposed)
exposure groups. Table 1 shows the distribution of 37 a priori
selected covariates across exposure groups and across the
sampled pseudo-exposed and pseudo-unexposed groups (co-
variate values for the pseudo-population were averaged over
all bootstrapped runs). New users of dabigatran were generally
healthier with fewer comorbidities than new users of warfarin
(Table 1) (31, 32). In general, differences between the pseudo-
exposed and pseudo-unexposed groups paralleled differences
between the dabigatran and warfarin groups (Table 1).
Table 2 shows that both PS and DRS matching resulted in
similar effect estimates, with hazard ratios of 0.88 (95% con-
fidence interval: 0.81, 0.95) and 0.87 (95% confidence inter-
val: 0.81, 0.94), respectively. The fitted PS model resulted in
good predictive performance and model fit in terms of dis-
crimination and calibration, with a C statistic of 0.73 and
Hosmer-Lemeshow P value of 0.18 (Table 2). The fitted
DRS also resulted in good discrimination, with a C statistic of
0.78, but poor calibration in terms of the Hosmer-Lemeshow
goodness-of-fit test, with a P value of <0.01 (Table 2). After
matching on the PS, exposure groups were approximately ba-
lanced on measured covariates with an average standardized
absolute mean difference of <0.01. Matching on the DRS re-
sulted in a pseudo-bias of approximately −0.02 (95% confi-
dence interval: −0.1, 0.06) (Table 2).
DISCUSSION
In this study, we used simulations and an empirical ex-
ample to compare metrics for evaluating DRS models in their
ability to reduce bias in effect estimates. We considered 2
traditional measures of model performance: the C statistic
and the P value from the Hosmer-Lemeshow goodness-of-fit
test. We also considered the dry-run method proposed by
Hansen where the PS is used to divide the unexposed popu-
lation into pseudo-exposed and pseudo-unexposed groups,
and the fitted DRS is then evaluated by its ability to control
for confounding within this pseudo-population (15).
In simulations, the pseudo-bias from the dry run had the
strongest correlation with bias in the effect estimate when the
functional form of the PS was a close approximation to the true
PS model. When there was moderate to severe misspecifica-
tion in the PS, this correlation was attenuated and the C statis-
tic showed a stronger correlation with bias in these settings.
The C statistic performed well when comparing the relative
performance of different models fitted to the same data set. In
practice, however, researchers will often fit a single model
and want to assess its validity in terms of confounding control.
In simulations, the C statistic showed little correlation with
bias after combining results across all simulation scenarios,
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Figure 4. Propensity score distributions across warfarin (A) and dabigatran (B) exposure groups in a population of Medicare beneficiaries, Uni-
ted States, 2010–2012.
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Table 1. Baseline Covariates Across Dabigatran andWarfarin Exposure Groups and Pseudo-Exposed and Pseudo-Unexposed Groups in a
Population of Medicare Beneficiaries, United States, 2010–2012
Warfarin (Unexposed)
(n = 56,260)
Dabigatran (Exposed)
(n = 11,407)
Pseudo-Unexposeda
(n = 46,774)
Pseudo-Exposeda
(n = 9,486)
No. of
Participants %
No. of
Participants %
No. of
Participants %
No. of
Participants %
Demographics
Mean age, years 78.9 76.8 79.3 77.1
White, % 50,185 89.2 10,462 91.7 41,514 88.8 8,671 91.4
Female sex, % 23,726 42.2 5,584 49.0 19,206 41.1 4,520 47.6
Diagnoses
Cardiovascular
Chest pain 21,608 38.4 3,998 35.0 18,270 39.1 3,338 35.2
Heart disease 41,945 74.6 7,599 66.6 35,535 76.0 6,410 67.6
Heart failure 17,297 30.7 2,194 19.2 15,291 32.7 2,006 21.1
Hypertension 36,616 65.1 7,221 63.3 30,598 65.4 6,018 63.4
Hyperlipidemia 19,807 35.2 4,687 41.1 16,032 34.3 3,775 39.8
Myocardial infarction 1,965 3.5 216 1.9 1,764 3.8 201 2.1
Cerebrovascular disease 11,979 21.3 1,982 17.4 10,253 21.9 1,726 18.2
Stroke
Ischemic 3,427 6.1 492 4.3 2,976 6.4 451 4.8
Hemorrhagic 189 0.3 18 0.2 173 0.4 16 0.2
TIA 3,882 6.9 723 6.3 3,264 7.0 618 6.5
VTE 5,829 10.4 191 1.7 5,627 12.0 202 2.1
Diabetes 19,744 35.1 3,424 30.0 16,801 35.9 2,943 31.0
Kidney disease 7,076 12.6 541 4.7 6,553 14.0 523 5.5
Renal failure 9,053 16.1 656 5.8 8,410 18.0 643 6.8
Bleeding 1,058 1.9 78 0.7 982 2.1 76 0.8
Anemia 8,792 15.6 1,135 10.0 7,788 16.6 1,004 10.6
Baseline medications
Antidepressant 15,902 28.3 2,611 22.9 13,664 29.2 2,238 23.6
Antihypertensive
ACE/ARB 29,377 52.2 5,730 50.2 24,567 52.5 4,810 50.7
Loop diuretic 23,018 40.9 3,274 28.7 20,075 42.9 2,943 31.0
Nonloop diuretic 29,565 52.6 4,788 42.0 25,379 54.3 4,186 44.1
Hypolipidemic
Statin 27,795 49.4 5,983 52.5 22,884 48.9 4,911 51.8
Fibrate 2,827 5.0 568 5.0 2,353 5.0 474 5.0
Rate control therapy
Beta blocker 39,850 70.8 8,212 72.0 33,062 70.7 6,788 71.6
CCB 24,739 44.0 4,768 41.8 20,730 44.3 4,009 42.3
Glycoside 10,401 18.5 1,951 17.1 8,734 18.7 1,667 17.6
Rhythm control therapy 10,745 19.1 2,648 23.2 8,684 18.6 2,061 21.7
Table continues
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illustrating that the actual value of a C statistic does not pro-
vide the best information for testing the validity of a single fit-
ted DRS model.
While the dry-run validation can assess whether a fitted
DRS model is insufficient in terms of confounding control, it
does not provide information on whether the lack of con-
founding control is due to model misspecification or model
extrapolation. Extrapolation being done by the risk score,
however, can potentially be mitigated by the process of fitting
and checking the validity of the PS (e.g., identifying positivity
violations). Although the presence of a few high-propensity
unexposed subjects could lead to especially problematic
extrapolation, this situation would reduce the pseudo-variance
relative to the pseudo-bias, increasing the likelihood of reject-
ing the risk score setup. In other words, the dry-run validation
penalizes a risk score for extrapolation.
A few limitations of the dry-run validation deserve atten-
tion. Because the dry run uses the PS to create sampling
probabilities, the method’s application is constrained by the
assumptions of the PS, even though analyses using the DRS
do not inherit these stronger assumptions. In particular, the PS
requires that there be no covariate patterns at which exposure
is received with certainty (i.e., positivity) (33). The DRS re-
quires a weaker condition, that there be no levels of disease
risk at which exposure is certain (i.e., risk positivity) (3).
While analyses using the DRS may include some individuals
for whom positivity is violated, the dry run’s application is
limited to the population where positivity holds. If the analyst
determines that positivity is violated when assessing the appro-
priateness of the fitted PS model, then the analyst must decide
whether to respecify the PS and try again, restrict the analysis
to a subgroup for which positivity does appear to hold, or seek
other modes of validation for the risk score model.
The dry-run analysis also requires accurate estimation of the
PS. In this case, one could simply use the PS for confounding
control. The DRS, however, can be valuable even when a
Table 1. Continued
Warfarin (Unexposed)
(n = 56,260)
Dabigatran (Exposed)
(n = 11,407)
Pseudo-Unexposeda
(n = 46,774)
Pseudo-Exposeda
(n = 9,486)
No. of
Participants %
No. of
Participants %
No. of
Participants %
No. of
Participants %
Health-care utilization, average
no. of claims
ECG 3.74 3.80 3.73 3.78
PSA 0.36 0.49 0.34 0.46
Fecal occult blood testing 0.12 0.13 0.11 0.13
Colonoscopy 0.14 0.14 0.14 0.14
Flu shot 0.76 0.79 0.75 0.79
Lipid assessment 1.52 1.72 1.48 1.68
Mammography 0.25 0.29 0.24 0.28
Pap smear 0.05 0.07 0.05 0.07
Abbreviations: ACE/ARB, angiotensin-converting enzyme/angiotensin II receptor blocker; CCB, calcium channel blockers; ECG, electrocardio-
graphy; PSA, prostate-specific antigen; TIA, transient ischemic attack; VTE, venous thromboembolism.
a Mean values for each covariate averaged over 1,000 sampled pseudo-populations. The total n and numbers of each covariate in the pseudo-
exposed and pseudo-unexposed groups were rounded to the nearest whole number.
Table 2. A Comparison of Effect Estimates on the Basis of Propensity Score or Disease Risk Score Matching in New Users of Dabigatran and
Warfarin in a Population of Medicare Beneficiaries (n = 67,667), United States, 2010–2012
Methoda HR 95% CI Pseudo-Biasb 95% CI ASAMDc C Statistic HL P Valued
Unadjusted 0.48 0.46, 0.50 −0.57 −0.65, −0.50 0.14
PS matching 0.88 0.81, 0.95 <0.01 0.73 0.18
DRSmatching 0.87 0.81, 0.94 −0.02 −0.10, 0.06 0.78 <0.01
Abbreviations: ASAMD, average standardized absolute mean difference; CI, confidence interval; DRS, disease risk score; HL, Hosmer-
Lemeshow; HR, hazard ratio; PS, propensity score.
a PS and DRS models included 200 empirically selected covariates and 37 covariates selected a priori.
b Bias in the pseudo–effect estimate on the log scale (averaged across 1,000 bootstrapped samples). The unadjusted pseudo-bias was calcu-
lated by taking the log of the unadjusted hazard ratio within the pseudo-population. The DRS-matched pseudo-bias was calculated by taking the
log of the hazard ratio obtained after matching pseudo-exposed to pseudo-unexposed subjects.
c ASAMD of covariates across exposure groups.
d P value from the Hosmer-Lemeshow goodness-of-fit test.
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correctly specified PS is available. As discussed in the Intro-
duction, risk scores are often preferred for evaluating effect
measure modification. The use of risk scores for evaluating ef-
fect modification, however, is challenging because misspecified
or overfitted DRS models can produce spurious suggestions of
effect modification across levels of disease risk (3, 15, 34). In
theory, the dry-run validation could be used to detect false sig-
nals of effect modification (15). If the modeling procedure pro-
duces risk scores that result in the appearance of effect
modification within the pseudo-population, this would bring
into question the value of the risk score setup for evaluating ef-
fect modification when applied to the full study population.
With a correctly specified PS, one may wish to evaluate a
DRS model by comparing results from DRS and PS analy-
ses. The dry-run strategy, however, maintains objectivity in
study design (35). By restricting to the unexposed popula-
tion when evaluating risk models, the dry-run analysis does
not allow information about the exposure-outcome associ-
ation to contribute to decisions on model selection. Re-
searchers can evaluate and modify fitted risk models within
the sampled pseudo-population without the risk of degrad-
ing inference (3, 15).
Finally, the optimal strategy for sampling from the unex-
posed population when performing a dry-run analysis remains
unclear. The without-replacement sampling outlined in this
study performed well for the scenarios considered. For smaller
samples, other without-replacement sampling techniques may
be more appropriate. These could include maximum entropy
sampling, which allows the analyst to explicitly specify the
number to be sampled (36), or a rejection sampling scheme
that throws out a particular pseudo-exposure group selection if
its size falls outside of a predetermined window. Regardless
of the sampling technique used, we emphasize that the dry-
run analysis does not provide information about bias caused
by unmeasured confounding. Subject-matter expertise is a
necessary component when performing PS or DRS analyses
(37, 38).
We conclude that accurately modeling the DRS within
the study cohort or within a historical set of unexposed sub-
jects presents unique challenges that are not shared by the
PS. Measures of predictive performance and goodness-of-fit
tests do not necessarily describe the ability of a DRS model
to control confounding. If the PS can be accurately modeled,
evaluating the ability of the DRS model to control con-
founding within a dry-run analysis can provide insight into
the validity of fitted DRS models.
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